Novo Nordisk
NVO
#19
Rank
โ‚ฌ452.08 B
Marketcap
99,59ย โ‚ฌ
Share price
-1.49%
Change (1 day)
9.21%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

EPS for Novo Nordisk (NVO)

EPS in 2023 (TTM): 2,65ย โ‚ฌ

According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is 2,70ย โ‚ฌ. In 2022 the company made an earnings per share (EPS) of 2,05ย โ‚ฌ an increase over its 2021 EPS that were of 1,88ย โ‚ฌ.

EPS history for Novo Nordisk from 1996 to 2023

Annual EPS

Year EPS Change
2023 (TTM)2,65ย โ‚ฌ29.3%
20222,05ย โ‚ฌ9.01%
20211,88ย โ‚ฌ15.08%
20201,64ย โ‚ฌ14.83%
20191,42ย โ‚ฌ-1.68%
20181,45ย โ‚ฌ4.96%
20171,38ย โ‚ฌ31.08%
20161,05ย โ‚ฌ-10.33%
20151,17ย โ‚ฌ13.91%
20141,03ย โ‚ฌ4.03%
20130,99ย โ‚ฌ-28.81%
20121,39ย โ‚ฌ108.9%
20110,67ย โ‚ฌ25.59%
20100,53ย โ‚ฌ35.01%
20090,39ย โ‚ฌ-9.17%
20080,43ย โ‚ฌ61.35%
20070,27ย โ‚ฌ28.96%
20060,21ย โ‚ฌ25.63%
20050,17ย โ‚ฌ4.17%
20040,16ย โ‚ฌ13.55%
20030,14ย โ‚ฌ36.87%
20020,10ย โ‚ฌ-6.99%
20010,11ย โ‚ฌ21.56%
20000,09044ย โ‚ฌ67.7%
19990,05393ย โ‚ฌ3.78%
19980,05196ย โ‚ฌ12.15%
19970,04634ย โ‚ฌ24.74%
19960,03714ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
1,76ย โ‚ฌ-34.87%๐Ÿ‡บ๐Ÿ‡ธ USA
5,13ย โ‚ฌ 90.12%๐Ÿ‡บ๐Ÿ‡ธ USA
3,75ย โ‚ฌ 39.02%๐Ÿ‡บ๐Ÿ‡ธ USA
3,01ย โ‚ฌ 11.36%๐Ÿ‡ซ๐Ÿ‡ท France